Company Registration No. 02916948 (England and Wales)

ANGLE TECHNOLOGY LIMITED DIRECTORS' REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2011

A59

A11QBN7V 31/01/2012 COMPANIES HOUSE

#290

COMPANY INFORMATION

Directors

Ian F Griffiths

Andrew D W Newland

Secretary

Ian F Griffiths

Company number

02916948

Registered office

3 Frederick Sanger Road The Surrey Research Park

Guildford Surrey GU2 7YD

Web site

www.ANGLEplc.com

Auditor

Baker Tilly UK Audit LLP The Clock House

140 London Road

Guildford Surrey GU1 IUW

CONTENTS

Page	
1 - 3	Directors' Report
4 - 5	Auditor's Report
6	Profit and Loss Account
7	Balance Sheet
8 – 20	Notes to the Financial Statements

DIRECTORS' REPORT FOR THE YEAR ENDED 30 APRIL 2011

The Directors present their Report and Financial Statements for ANGLE Technology Limited, Company registration number 02916948, for the year ended 30 April 2011.

The Directors who held office as at the date of approval of this Directors' Report confirm that, so far as they are each aware, there is no relevant audit information of which the company auditors are unaware; and each Director has taken all the steps that they ought to have taken as a director to make themselves aware of any relevant audit information and to establish that the company auditors are aware of that information.

Principal activity and review of the business

The Company is a key trading Company of ANGLE plc and the former holding company of the Group. The principal activities of the Company are the provision of Management services and it also holds a number of investments in ventures.

Management services

The Management services business has been constrained by Government cut backs and in the circumstances this part of the business has performed well to maintain revenues and profitability, although this is expected to reduce next year given ongoing austerity measures.

Our established Management services contracts will continue to be closely managed and are expected to remain profitable, although we expect a drop in revenues as contracts complete and some of them do not renew. Set against this, a number of new contracts are coming to the market for tender.

Investments

Acolyte Biomedica (medical diagnostics / MRSA detection) was sold in February 2007. The deferred consideration of up to £3 million due in respect of the sale of the investment in Acolyte Biomedica is subject to dispute between the former Acolyte shareholders and the purchaser, 3M Corporation.

The legal action in the UK courts by the former major Acolyte shareholder, Porton Capital, against the purchaser, 3M, in respect of its share of the earn-out concluded after the year end on 7 November 2011 when the judge handed down his judgement.

The judge found in favour of Porton Capital and in particular that 3M was "in breach of its obligation diligently to seek regulatory approval for Baclite in the US" and "in material breach of its obligation actively to market [Baclite]".

However the damages awarded against 3M were lower than expected and limited to only US\$1,299,808, which on a comparable basis would equate to US\$158,848 for ANGLE Technology's share of the earn-out. The Company is currently awaiting any possible further developments in the case and in particular whether the judgment is appealed by Porton Capital which may lead to a change in the level of the award.

Once the situation is known, ANGLE expects to pursue its own claim against the purchaser. At present the Company has no exposure to legal costs.

The change in circumstances associated with this judgement results in an adjusting post balance sheet event. The Directors believe that it is appropriate to impair the value the asset by £860,608 to £98,413 being the fair value based on the damages awarded.

DIRECTORS' REPORT (Continued) FOR THE YEAR ENDED 30 APRIL 2011

Investments (continued)

NeuroTargets (neuropathic pain, Alzheimer's and multiple sclerosis) has developed therapeutic molecules based on galanin, a protein used by nerve cells to communicate with each other. NeuroTargets agreed a licensing deal with the University of Bristol, and the Wellcome Trust during the year with a funding award from the Wellcome Trust to the University to progress the galanin programme. However, as is often the case, side effects were found in the first set of targets being investigated by the University and new targets are currently being sought. The University's Wellcome Trust funding programme has been terminated whilst this process is underway and the University will need to reapply for the funding if the programme is to progress. In addition to the work on neuropathic pain, NeuroTargets has through Professor Wynick's research also had positive pre-clinical results for the treatment of multiple sclerosis (MS) and Alzheimer's disease (AD). NeuroTargets has secured a granted patent in Australia for the use of galanin to treat MS and AD and applications in other territories are ongoing. NeuroTargets has long term potential that requires partnering.

During the year ANGLE increased its holding in NeuroTargets to 65% following the conversion of a loan after the expiry of its fifth anniversary, thus changing the status of NeuroTargets from investment to a subsidiary.

Additional information is provided in the ANGLE plc Annual Report and Accounts 2011 and subsequent news releases.

The key performance indicators for the Company are those associated with Management services and the above investments. Management services – to retain existing contracts as far as possible, win new management services contracts, retain key employees and operate contracts profitably and contribute to corporate overheads. Investments: 1) for Acolyte – to secure the maximum settlement possible and get the cash paid promptly and 2) for NeuroTargets to successfully identify new targets and secure a new deal with the University of Bristol / Wellcome Trust.

Principal risks and uncertainties

The Directors consider that the Company is exposed to number of risks and uncertainties:

- the failure to secure sufficient new management services contracts or a public sector squeeze on existing contracts such that the operating costs of the business are not covered;
- the nature of the activities of the investments means there is considerable technical and market risk, particularly with regard to biotech, which may result in delays, increased costs or ultimately failure of one or more of the investments, which could significantly affect the overall value of the Group;
- the early stage investment market remains challenging and there may be delays in securing investment and / or corporate partnerships together with pressures on prices in portfolio companies; portfolio companies may require further support from the Group;
- the exit environment remains challenging and there may be pressures on prices and / or delays in securing cash exits;
- In the event that new funds are required there can be no guarantee that these will be available; and
- the loss of key personnel.

DIRECTORS' REPORT (Continued) FOR THE YEAR ENDED 30 APRIL 2011

Results and dividends

The results for the year are set out on page 6. The Directors do not recommend the payment of a dividend for the year.

Directors

The following Directors have held office since 1 May 2010:

G P Evans (resigned 23 March 2011) A D W Newland I F Griffiths

Auditor

The auditor Baker Tilly UK Audit LLP, Chartered Accountants, has indicated its willingness to continue in office.

Directors' responsibilities

The Directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the Board

I F Griffiths **Director**

31 January 2012

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ANGLE TECHNOLOGY LIMITED

We have audited the Financial Statements on pages 6 to 20. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As more fully explained in the Directors' Responsibilities Statement on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the APB's website at www.frc.org_uk/apb/scope/private.cfm.

Opinion on the financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 30 April 2011 and
 of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ANGLE TECHNOLOGY LIMITED (Continued)

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- · certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit

Colin Roberts (Senior Statutory Auditor)

For and on behalf of Baker Tilly UK Audit LLP, Statutory Auditor

, alw filly ox Abil W

Chartered Accountants

The Clock House

140 London Road

Guildford

Surrey

GU1 1UW

31 January 2012

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 30 APRIL 2011

	Notes	2011 £	2010 £
Turnover	2	2,358,273	2,369,067
Operating costs	3	(2,085,898)	(2,228,402)
Operating profit from Management servi	ces	272,375	140,665
Provision to write off Group balances	20	(1,337,723)	(870,462)
Operating profit /(loss)		(1,065,348)	(729,797)
Profit /(loss) on increase /(decrease) in value of current asset investment	10	-	597,608
Profit /(loss) on increase /(decrease) in value of other receivables	12	(860,608)	-
Net interest	6	753	(507)
Profit /(loss) on ordinary activities before taxation		(1,925,203)	(132,696)
Tax on profit /(loss) on ordinary activitie	s 7	-	(5,921)
Retained profit /(loss) for the year	17	(1,925,203) ======	(138,617)

The profit and loss account has been prepared on the basis that all operations are continuing operations.

There are no recognised gains and losses other than those passing through the profit and loss account.

BALANCE SHEET AS AT 30 APRIL 2011

Company no: 02916948

	Natas	2011	2010
	Notes	£	£
Fixed assets			
Tangible assets	8	9,876	14,556
Investments	9	967	967
		10,843	15,523
Current assets			
Investments	10		-
Investments – ESOT	11	102,172	342,115
Debtors – due within one year	12	251,239	422,102
Debtors – due after one year	12	98,413	1,007,963
Cash at bank and in hand		180,225	831,298
		632,049	2,603,478
Creditors: amounts falling due		(222)	(000.04.4)
within one year	13	(233,700)	(800,314)
Net current assets /(liabilities)		398,349	1,803,164
Total assets less current liabiliti	es	409,192	1,818,687
Creditores amounts falling due			
Creditors: amounts falling due after more than one year	14	(9,248,664)	(8,782,014)
arter more than one year	17	(9,240,004)	(0,702,014)
Net assets /(liabilities)		(8,839,472)	(6,963,327)
, (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		======	=======
Capital and reserves			
Called up share capital	15	1,044,649	1,044,649
Share premium account	17	2,553,356	2,553,356
Capital contribution reserve	17	379,395	571,982
Profit and loss account	17	(13,186,872)	(11,475,429)
ESOT shares	17	370,000	342,115
Shareholders' funds /(deficit)	18	(8,839,472)	(6,963,327)
•		=======	=======

The Financial Statements on pages 6 to 20 were approved by the Board of Directors and authorised for issue on 31 January 2012 and are signed on its behalf by:

A D W Newland

Director

I F Griffiths **Director**

your Griffiths

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2011

1 Accounting policies

1.1 Accounting convention

The Financial Statements are prepared under the historical cost convention and on the going concern basis and in accordance with applicable United Kingdom accounting standards.

The Directors have, in accordance with the Companies Act 2006, departed from the standard format of the profit and loss account in presenting the Financial Statements. Profits and losses on disposals or impairments of fixed asset investments are included within operating profit as these represent a return from a principal class of business activity. Where the disposal is not entirely in cash, for example, it includes shares or an earn-out, then any subsequent change in value is outside of the Company's control and is shown below operating profit. Other material disposals of fixed assets, such as property, that are not part of the main business activities are shown below operating profit in accordance with the Companies Act 2006 and Financial Reporting Standard 3 — Reporting Financial Performance.

On the grounds the Company is a subsidiary where 90% or more of the voting rights are controlled within the Group and the results are contained in the consolidated accounts, the Company has taken advantage of the exemption conferred by Financial Reporting Standard 1 and has therefore not prepared a cash flow statement.

1.2 Group accounts

The Financial Statements present information about the Company as an individual undertaking and not about it as a group. The Company has not prepared group accounts as it is exempt from the requirement to do so by the Companies Act 2006 as it is a subsidiary undertaking of ANGLE plc, a company incorporated in Great Britain, and is included in the consolidated accounts of that company.

1.3 Going concern

The Directors of the ultimate parent company, ANGLE plc have confirmed their intention to continue to provide financial support to the Company.

The Financial Statements have been prepared on a going concern basis which assumes that the Company will be able to continue in operational existence for the foreseeable future. The validity of this assumption depends on the ultimate parent company continuing to provide the funds necessary to support and develop the Company.

If the Company were unable to continue in operational existence for the foreseeable future, adjustments would have to be made to reduce the balance sheet values of assets to their recoverable amounts, to provide for further liabilities that might arise and to reclassify fixed assets and long term liabilities as current assets and liabilities.

The Directors have prepared and reviewed the financial projections for the 12 month period from the date of signing of these Financial Statements and based on the projected income and expenditure and financial support of the ultimate parent company, the Directors have a reasonable expectation that the Company has adequate resources to continue in business for the foreseeable future. Accordingly the going concern basis has been used in preparing the Financial Statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2011

1 Accounting policies (continued)

1.4 Turnover

Turnover represents amounts receivable for goods and services net of value added tax. Management services revenues are recognised in proportion to the stage of completion of each project. The stage of completion takes into account the milestones achieved in relation to the project deliverables.

1.5 Pensions

Pension costs are charged against profits as they fall due and represent the amount of contributions payable to employee personal pension schemes on an individual basis, which is in line with Financial Reporting Standard 17. The company has no further payment obligations once the contributions have been paid.

1.6 Deferred taxation

Deferred taxation is provided in full on timing differences which result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based upon tax rates that have been enacted or substantially enacted at the reporting date. Deferred tax assets are recognised to the extent that it is regarded as more likely than not that they will be recovered. Deferred tax assets and liabilities are not discounted.

1.7 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions denominated in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to the profit and loss account.

1.8 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Computer equipment 33.33% Straight line Fixtures, fittings & equipment 33.33% Straight line

1.9 Leases

Assets obtained under hire purchase contracts and finance leases, and any other leases that entail taking substantially all the risks and rewards of ownership of an asset, are capitalised on the balance sheet and depreciated over the shorter of the lease term and their useful lives. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period. Leases that do not meet the definition of finance leases are accounted for as operating leases. The rentals payable are charged to the profit and loss account as incurred.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2011

1 Accounting policies (continued)

1.10 Fixed asset investments

Fixed asset investments are carried at the lower of pre-transaction carrying amount or cost, less provision for permanent diminution in value. Carrying values are reviewed on a regular basis by the Directors. Provisions for permanent diminution in value are based upon an assessment of events or changes in circumstances that indicate an impairment has occurred.

In furtherance of its core activity of commercialising technology, the Company invests sums towards the establishment and development of new Technology Ventures. These expenditures are capitalised as the Company's cost of investment and take the form of seed funding to cover management costs and expenses, external market research, professional fees, technology research and development and IP acquisition costs. Each project is entered into in the expectation of establishing highly valuable technology ventures in which the Company retains a significant equity stake that has the potential for disposal at a high commercial return.

The Company holds all equity investments exclusively as part of its investment portfolio, with a view to their disposal and the ultimate realisation of capital gains.

The Directors consider that treating all investments consistently as a single asset class allows a better understanding of the Company's activities by removing the accounting variability of associate accounting methods.

All of the Company's participating interests are in companies and are referred to as "investments" throughout these Financial Statements.

1.11 Current asset investments

Short term investments are classified as current assets and are valued at the bid price at the balance sheet date.

1.12 Other receivables

Other receivables comprise the potential return from earn-outs or legal actions and are classified as current assets and shown as a debtor. Earn outs are a deferred payment conditional on the future performance of the acquired asset and are shown on the balance sheet at an estimated value. The Directors consider a number of valuation methodologies including a "balance of probabilities" and discounted cash flow in order to determine value. The earn-out is revalued based on any new information received relating to progress against plans, levels of sales and any other relevant factors. Legal actions may arise where the acquirer has not performed in accordance with the Share Purchase Agreement and, where the Directors believe there is a strong case, this is shown on the balance sheet at an estimated value of the payout. The value may be revised as future information becomes available.

1.13 Share based payments

The Company's ultimate parent company ANGLE plc operates share based payment schemes for employees of the ANGLE Group which allow employees to acquire or receive shares in ANGLE plc. The fair value of options granted by ANGLE plc is recognised as an employee expense by the Company with a corresponding increase in equity. Note 1.10 of the ANGLE plc Annual Report and Accounts 2011 provides additional details on the basis for determining the valuation and charge.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

1.14 Employee Share Ownership Trust

The Company has an Employee Share Ownership Trust (ESOT) to assist with the obligations under share option and other employee remuneration schemes. The Company, as sponsoring entity, is deemed to have de facto control of the ESOT in accordance with UITF 38: Accounting for ESOP Trusts, and therefore accounts for this as an extension of its own business including it in the assets and liabilities of the Company to the extent that shares have not yet vested unconditionally in beneficiaries.

Shares in ANGLE plc held by the ESOT are stated at cost and presented in the Balance Sheet as an investment under the heading of ESOT shares. Finance and administrative costs relating to the ESOT are charged to operating costs as incurred.

2 Turnover

The total turnover of the Company for the year has been primarily derived from its Management services activities. Some £0.1million (2010: £0.2 million) of the fees relate to reimbursable operating expenditure incurred on management contracts. In addition the Company manages a grant voucher scheme on behalf of the London Development Agency. The gross value of the vouchers paid during the year ended 30 April 2011, of £0.8 million (2010: £1.0 million) was passed through the Company's books as both income and expenditure, however, due to revenue recognition rules this is classified as "agency" revenues and is not shown in our total revenues below.

The geographical analysis, as defined by the country or area in which the client is based, is as follows:

		2011 £	2010 £
	United Kingdom Middle East	2,358,273 -	2,336,575 32,492
		2,358,273 ======	2,369,067
3	Operating costs	2011 £	2010 £
	Staff costs (Note 5) Staff costs recharged to group companies Depreciation Loss on disposal of fixed assets Auditor's remuneration – audit work Auditor's remuneration - non-audit work Bad debt expense Exchange (gains) / losses Other operating costs	1,819,066 (326,608) 8,731 661 56,350 17,348 4,000 (3,384) 509,734	1,692,747 (309,660) 8,804 1,298 38,400 26,835 - 2,775 767,203
		2,085,898 ======	2,228,402 ======

ANGLE plc and ANGLE Technology Limited employ all UK Directors and staff who provide resources to other group companies as required. Non ANGLE plc and ANGLE Technology Limited costs are recharged to other group companies.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

4	Directors' emoluments	2011 £	2010 £
	Emoluments for qualifying services	294,788 ======	267,805 ======
	Emoluments disclosed above include the following amounts paid Director:	i to the hig	ghest paid
	Emoluments for qualifying services	163,495	164,170

Pension contributions for Directors were £148,967 (2010: £152,009). Retirement benefits are accruing to one Director into an employee personal pension scheme.

5 Employment

Employment costs

The aggregate employment costs of staff (including Directors) for the year was:

	2011 £	2010 £
Wages and salaries	1,486,049	1,348,981
Social security costs	162,877	146,981
Other pension costs	148,967	152,177
	1,797,893	1,648,139
Employee share based payment charge (Note 16)	21,173	44,608
	1,819,066	1,692,747
	======	======

The pension costs payments are made directly to individuals' personal pension plans.

Number of employees

The average monthly number of employees (including Directors) during the year was:

	2011 Number	2010 Number
Executives	31	22
Administration	10	10
	41	32
	=====	=====

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

6	Net interest	2011 £	2010 £
	Interest receivable	753	348
	Interest payable Other	-	(855)
	Net interest	753 =====	(507)
7	Tax on profit / (loss) on ordinary activities	2011 £	2010 £
	Current tax: UK corporation tax Adjustments in respect of previous periods	- -	- 5,921
	Tax on loss on ordinary activities	-	5,921
	Deferred tax: Origination and reversal of timing differences	-	-
	Tax on loss on ordinary activities	-	5,921 =====
	UK corporation tax Profit / (loss) on ordinary activities before tax	(1,925,203) ======	(132,696)
	Tax on profit / (loss) on ordinary activities at 28% (2010: 28%)	(539,057)	(37,155)
	Factors affecting charge: Capital allowances for period in excess of depreciation Disallowable expenses Provision against group balances Group loss relief Capital transactions Share based payments charge Other tax adjustments	(2,995) 198 374,563 (70,135) 240,970 5,929 (9,473)	2,707 979 243,729 (67,025) (167,330) 12,490 11,605
	Current tax charge for year	-	-======

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

8	Tangible fixed assets					
	_		•	Computer equipment	Fixtures, fittings & equipment	Total
				£	£	£
	Cost			_	_	_
	At 1 May 2010			130,206	50,140	180,346
	Additions			3,524	1,188	4,712
	Disposals			(36,639)	-,100	(36,639)
	5.5pc5a.5					
	At 30 April 2011			97,091	51,328	148,419
	Depreciation					
	At 1 May 2010			118,449	47,341	165,790
	Charge for the year			8,632	99	8,731
	Disposals			(35,978)	-	(35,978)
	At 30 April 2011			91,103	47,440	138,543
	Net book value					
	At 30 April 2011			5,988	3,888	9,876
				=====	-	=====
	At 30 Aprıl 2010			11,757	2,799	14,556
				=====	=====	=====
9	Fixed asset investments					
9	rixed asset investments	Shares	Loans	Shares	Loans	Total
		subsidiaries	subsidiaries	investments	investments	iotai
		£	£	£	£	£
	Cost					
	At 1 May 2010	967	-	50,000	189,461	240,428
	Transfer to subsidiary status	50,000	189,461	(50,000)	(189,461)	-
	At 30 April 2011	50,967	189,461			240,428
	•	=====	======	=====	=====	======
	Net Book Value					
	At 1 May 2010 & 30 April 2011	967	-	-	-	967
		=====	=====	=====	======	=====

At the start of the year the Company had the potential right to convert certain loans into shares in NeuroTargets Limited, however, at that time there was no economic case for conversion. NeuroTargets made commercial progress and its licensing partner announced on 16 July 2010 further funding from Wellcome Trust to progress its IP and technology development. One of the loans was repayable in September 2010 following the expiry of the fifth anniversary of the Loan Agreement. The loan was converted resulting in a transfer from investment to subsidiary status.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

9 Fixed asset investments (continued)

Holdings of more than 20%

The Company holds more than 20% of the share capital of the following companies:

Company	Country of registra	ition Share:	Shares held	
-	or incorporation	Class	%	
Subsidiaries	-			
ANGLE Technology Licensing Limited	England & Wales	Ordinary	100	
ANGLE Technology Ventures Limited	England & Wales	Ordinary	100	
Progeny bioVentures Limited	England & Wales	Ordinary	96.5	
NeuroTargets Limited ⁽¹⁾	England & Wales	Ordinary	55	
ANGLE Technology LLC	USA	Membership Units	100	

⁽¹⁾ The effective holdings shown are before a) the effects of any dilutive share options or warrants or convertible loans and b) additional ANGLE holdings from convertible loans or warrants within the individual investments

The principal activity of these undertakings for the last relevant financial year was as follows:

Subsidiaries	Principal activity
ANGLE Technology Licensing Limited	Dormant
ANGLE Technology Ventures Limited	Establishment and growth of technology companies
Progeny bioVentures Limited	Establishment and growth of biotech companies
NeuroTargets Limited	New drug targets
ANGLE Technology LLC	US subsidiary covering all of Group's business

10	Current asset investments	2011 £	2010 £
	Net book value	_	_
	At 1 May	-	243,412
	Disposal proceeds	-	(841,020)
	Profit / (loss) on disposal	-	597,608
	At 30 April		
		======	======
	Market value		
	Listed investments at 30 April	-	-
		======	======

Current asset investments are valued at the bid price at the balance sheet date. They comprised shares in Provexis plc which is listed on the Alternative Investment Market.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

11	Employee Share Ownership Trust	2011 £	2010 £
	Cost	_	L
	At 1 May	342,115	342,115
	Disposals	(239,943)	-
	At 30 April	102,172	342,115
	·	======	
	Market value		
	At 30 April	28,032	99,838
		======	======

The Employee Share Ownership Trust (ESOT) held 113,259 (2010: 300,264) ANGLE plc shares at the year end. During the year the basis for determining the remaining cost has been changed from using the market value at date of disposal to a market value based on the weighted average purchase cost. Shares purchased by the ANGLE ESOT are used (disposed) to assist in meeting the obligations under employee remuneration schemes.

The Trustee has waived its right to receive dividends on the shares held by the Trust. The purchase of the shares is funded by an interest free loan from ANGLE Technology Limited.

12	Debtors	2011 £	2010 £
	Amounts falling due within one year:	_	_
	Trade debtors	177,423	264,389
	Other debtors		1,408
	Prepayments and accrued income	73,816	156,305
		251,239	422,102
		======	=====
	Amounts falling due after more than one year:		
	Other receivables	98,413	959,021
	Amounts owed by Investments	•	48,942
		98,413	1,007,963
		======	======

Other receivables relates to the fair value ascribed to the eventual return expected from the sale of Acolyte Biomedica. Acolyte Biomedica (medical diagnostics / MRSA detection) was sold in February 2007. ANGLE was due an earn-out of up to £3 million receivable early in 2010. This is subject to dispute between the former Acolyte shareholders and the purchaser.

The legal action by the former major Acolyte shareholder, Porton Capital, in the UK courts against the purchaser, 3M, in respect of its share of the earn-out concluded after year end on 7 November 2011 when the judge handed down his judgement.

The judge found in favour of Porton Capital and in particular that 3M was "in breach of its obligation diligently to seek regulatory approval for Baclite in the US" and "in material breach of its obligation actively to market [Baclite]".

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

12 Debtors (continued)

However the damages awarded against 3M were limited to only US\$1,299,808, which on a comparable basis would equate to US\$89,605 for ANGLE Technology's earn-out.

These circumstances result in an adjusting post balance sheet event. The Directors believe that it is appropriate to impair the value the asset by £860,608 to £98,413 being the fair value based on the Court judgement.

ANGLE is currently awaiting any possible further developments in the case and in particular whether the judgment is appealed by Porton Capital which may lead to a change in the level of the award.

Once the situation is known, ANGLE expects to pursue its own claim against the purchaser. At present the Company has no exposure to legal costs.

13	Creditors: amounts falling due within one year	2011 £	2010 £
	Trade creditors	43,979	•
	Other taxes and social security costs		59,045
	Other creditors	•	43,437
	Accruals and deferred income	107,345	200,100
		233,700	800,314
		======	~~~===
14	Creditors: amounts falling due after more than one year	2011 £	2010 £
	Amounts owed to group undertakings	9,248,664 =====	8,782,014 ======
15	Share capital	2011 £	2010 £
	Allotted, called up and fully paid		
	10,446,484 (2010: 10,446,484) Ordinary shares of 10p each	1,044,649	1,044,649
		======	======

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

16 Share based payments

Share option scheme

All shares referred to are those of ANGLE plc. Note 23 of the ANGLE plc Annual Report and Accounts 2011 provides additional details on the terms and conditions of the share based arrangements and the basis for determining the valuation and charge.

The movement in the number of employee share options is set out below:

2011 Number of share options #	2011 Weighted average exercise price (p)	2010 Number of share options #	2010 Weighted average exercise price (p)
1,720,025	99.1	2,421,280	100.6
-	-	-	-
-	-	-	-
(625,000)	116.5	(700,461)	104.3
(85,397)	128.3	(794)	126.0
1,009,628	85.8	1,720,025	99.1
======	======	======	======
1,009,628	85.8 ======	1,720,025	99.1
	Number of share options # 1,720,025 (625,000) (85,397) 1,009,628	Number of share options # weighted average exercise price (p) 1,720,025 99.1	Number of share options Weighted average exercise price (p) Number of share options price (p) 1,720,025 99.1 2,421,280 (625,000) 116.5 (700,461) (85,397) 128.3 (794) 1,009,628 85.8 1,720,025 ======= ====================================

Options are issued at market price, with the exception of one tranche which were issued at the placing price. The options outstanding at 30 April 2011 had a weighted average remaining contractual life of one year and eleven months (2010: two years and two months).

Deferred Annual Bonus Scheme

Bonuses under the Deferred Annual Bonus (DAB) scheme are paid partly in cash and partly in deferred shares. The cash element is accrued in the year it relates to and is included in wages and salaries. The deferred shares, comprising Mandatory and Matching shares, are deferred for three years at which point they vest. Awards are forfeited if the employee leaves the Group before the awards vest, unless the conditions under which they leave are such that they are considered to be a "good leaver"; in which case their award is released.

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

16 Share based payments (continued)

Deferred Annual Bonus Scheme (continued)

The movement in the number of DAB scheme shares is set out below:

2011 Number of DAB shares #	2011 Weighted average award price(p)	2010 Number of DAB shares #	2010 Weighted average award price(p)
411,408	25.0	415,256	25.0
(187,005)	28.0	(3,848)	28.0
224,403	22.5	411,408	25.0
-		<u>-</u>	-
	Number of DAB shares # 411,408 (187,005)	Number of DAB shares # weighted average award price(p) 411,408 25.0 (187,005) 28.0	Number of DAB shares shares Weighted average award price(p) Number of DAB shares shares # 25.0 415,256 (187,005) 28.0 - - (3,848)

Awards were made at market price. The awards exercised in the year had a weighted average exercise price of 18.25p. The awards outstanding at 30 April 2011 had a weighted average remaining contractual life of three months (2010: ten months).

The share based payment charge for the share option scheme and DAB scheme was £21,173 (2010: £44,608).

17 Statement of movements on reserves

	ESOT shares	Capital contribution reserve	Share Profit and premium loss account account
	£	£	£ £
At 1 May 2010	342,115	571,982	2,553,356 (11,475,429)
Retained profit / (loss) for the year	-	-	- (1,925,203)
Share based payments charge	-	21,173	
Share based payments release	-	(213,760)	- 213,760
ESOT shares	27,885	• • •	
At 30 April 2011	370,000	379,395	2,553,356 (13,186,872)

18 Reconciliation of movements in Shareholders' funds /(deficit)

£	-
_	£
(1,925,203)	(138,617)
21,173	44,608
27,885	-
(6,963,327)	(6,869,318)
(8,839,472)	(6,963,327)
(21,173 27,885 (6,963,327)

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 30 APRIL 2011

19 Guarantees and other financial commitments

The Company leases office accommodation on leases of generally less than one year with monthly rental payments and short notice periods. The Company also has a number of retainers with professional advisors which can be terminated on short notice periods.

The Company provides ongoing financial support to its controlled investments, typically on a rolling basis. The Company has no contractual commitment to continue to provide funding.

20 Related party transactions

During the year the Company provided Progeny bioVentures Limited with executive management and support services of £5,566 (2010: £13,258). There is an outstanding liability at the end of the year in respect of these services as follows:

	2011 £	2010 £
Amounts owed by Progeny bioVentures Less provision	1,607,365 (1,551,850)	1,601,488 (1,056,982)
	55,515	544,506

Provision to write off Group balances

The provision reflects the Directors' view of existing valuation circumstances for investments and the potential impact of current adverse economic conditions on the long term value of the amounts owed by subsidiary undertakings and their ability to repay them and an investment value adjustment on the ESOT.

The Company has taken advantage of the exemption provided by FRS8 and has not disclosed transactions entered into between two or more subsidiaries of the Group where these subsidiaries are wholly owned within the group.

Directors' interests

The Directors that are Directors of ANGLE plc, have voluntarily waived part of their emoluments with effect from December 2008. At the balance sheet date £nil (2010: £19,030) of salary and £8,762 (2010: £35,268) of pension was due to Ian Griffiths and Andrew Newland respectively.

21 Post Balance Sheet

Following the year end, the Company has agreed to invest in Novocellus up tp £0.5 million to contribute to the costs of the clinical trials with Novocellus' partner ORIGIO.

22 Control

The parent undertaking of the largest group for which group accounts are prepared and of which the company is a member is ANGLE Plc, the company's ultimate holding company, which is registered in England. Copies of these group accounts are available from Companies House, Crown Way, Maindy, Cardiff, CF14 3UZ.